1
|
Scarr E, Craig JM, Cairns MJ, Seo MS, Galati JC, Beveridge NJ, Gibbons A, Juzva S, Weinrich B, Parkinson-Bates M, Carroll AP, Saffery R, Dean B. Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Transl Psychiatry 2013; 3:e230. [PMID: 23423139 PMCID: PMC3594731 DOI: 10.1038/tp.2013.3] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Many studies have shown decreased cortical muscarinic M1 receptors (CHRM1) in schizophrenia (Sz), with one study showing Sz can be separated into two populations based on a marked loss of CHRM1 (-75%) in -25% of people (Def-Sz) with the disorder. To better understand the mechanism contributing to the loss of CHRM1 in Def-Sz, we measured specific markers of gene expression in the cortex of people with Sz as a whole, people differentiated into Def-Sz and people with Sz that do not have a deficit in cortical CHRM1 (Non-Def-Sz) and health controls. We now report that cortical CHRM1 gene promoter methylation and CHRM1 mRNA are decrease in Sz, Def-Sz and Non-Def-Sz but levels of the micro RNA (miR)-107, a CHRM1 targeting miR, are increased only in Def-Sz. We also report in vitro data strongly supporting the notion that miR-107 levels regulate CHRM1 expression. These data suggest there is a reversal of the expected inverse relationship between gene promoter methylation and CHRM1 mRNA in people with Sz and that a breakdown in gene promoter methylation control of CHRM1 expression is contributing to the global pathophysiology of the syndrome. In addition, our data argues that increased levels of at least one miR, miR-107, is contributing to the marked loss of cortical CHRM1 in Def-Sz and this may be a differentiating pathophysiology. These latter data continue to support the hypothesis that microRNAs (miRNA) have a role in the underlying neurobiology of Sz but argue they are differentially affected in subsets of people within that syndrome.
Collapse
Affiliation(s)
- E Scarr
- The Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
| | - J M Craig
- The Early Life Epigenetic Group, The Murdoch's Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia,The Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
| | - M J Cairns
- The School of Biomedical Sciences and Pharmacy, and Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia,The Schizophrenia Research Institute, University of Sydney, Sydney, New South Wales, Australia
| | - M S Seo
- The Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia,The Molecular Psychiatry Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - J C Galati
- The Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia,Department of Mathematics and Statistics, La Trobe University, Bundoora, Victoria, Australia
| | - N J Beveridge
- The School of Biomedical Sciences and Pharmacy, and Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia,The Schizophrenia Research Institute, University of Sydney, Sydney, New South Wales, Australia
| | - A Gibbons
- The Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia,The Molecular Psychiatry Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - S Juzva
- The Molecular Psychiatry Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - B Weinrich
- The Early Life Epigenetic Group, The Murdoch's Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia
| | - M Parkinson-Bates
- The Cancer and the Developmental Epigenetics Group, The Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia
| | - A P Carroll
- The School of Biomedical Sciences and Pharmacy, and Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia,The Schizophrenia Research Institute, University of Sydney, Sydney, New South Wales, Australia
| | - R Saffery
- The Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia,The Cancer and the Developmental Epigenetics Group, The Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia
| | - B Dean
- The Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia,The Molecular Psychiatry Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia,Molecular Psychiatry Laboratory, The Mental Health Research Institute, The Kenneth Myer Building, The University of Melbourne, Genetics Lane, Parkville, Victoria 3010, Australia. E-mail:
| |
Collapse
|